Summary of our psychedelics podcast series: “Micro-dosing with Zeifmans”

Innovations in psychedelics are poised to disrupt the pharmaceutical industry, and the Zeifmans Cannabis and Psychedelics Team has been hard at work in the space and is here to demystify these interesting developments. We’re proud to announce our entry into podcasting, having recently launched a brand-new endeavor: “Micro-dosing with Zeifmans”. To listen, look us up on any of the following platforms:

  • Apple Podcasts
  • Spotify
  • Google podcasts
  • Breaker
  • Overcast
  • Pocket Casts
  • Radio Public

Our 6-part series explores the business of psychedelics, with weekly special guests from the industry including:

  • Todd Shapiro, Co-Founder, CEO and Director of Red Light Holland
  • Ronan Levy, Founder and Executive of Field Trip Health
  • Bruce Linton, Founder and former Chairman and CEO of Canopy Growth Corporation
  • Dr. Joe Tucker, CEO of MagicMed Industries Inc.

What are psychedelics?

Psychedelics include molecules like psilocybin (commonly referred to as magic mushrooms), ayahuasca, ketamine, LSD and MDMA (commonly referred to as ecstasy). As we’ve discussed in a previous blog post, recent clinical trials have proven that psychedelics have impressive efficacy in treating a variety of illnesses including depression, anxiety, PTSD and traumatic brain injury. Though the majority of these substances are still illegal, regulations are changing quickly in the wake of such encouraging research results. And it’s this data that is driving the growth of the industry on a global scale.

Though often compared to the cannabis industry, there are several distinctions that are covered in detail within the podcast series. That being said, as the epicentre of cannabis finance, Canada’s unique position has facilitated our country’s opportunity to play a key role in the psychedelics industry.

Episode guide:

Special Guests: James Lanthier, CEO of Mindset Pharma and Henri-Sant Cassia, Founding-Partner of the Conscious Fund.

Special Guests: Todd Shapiro, Co-founder, CEO and Director of Red Light Holland and Jeffery Merk, Partner at Aird & Berlis LLP.

Special Guests: Anna Serin, Director of Listings at The CSE and Bill O’Hara, Managing Director at Haywood Securities Inc.

Special guests: Danny Motyka, CEO of Psygen Labs, Daniel Cohen, CEO of Pharmadrug Inc. and Carl Saling, Founder, CEO and Director of Hollister Biosciences Inc.

Special guests: Ronan Levy, Founder and Executive of Field Trip Health, and Susan Chapelle, Co-CEO of Havn Life.

Special guest: Bruce Linton, Founder and former Chairman and Chief Executive Officer at Canopy Growth Corporation.

Special guests: David Wood and Cameron MacDonald, both Partners at BLG and  Dr. Joseph Tucker, CEO of MagicMed Industries Inc.


Join us as we touch base with industry experts to discuss the latest data, trends, insights, and look ahead to the future of psychedelics business in Canada and beyond.

For information on how our services can help your psychedelics business activities, contact our team today.


Q&A with Partner, Jennifer Chasson

Q&A with Partner, Jennifer Chasson

With over 25 years of experience and 100+ successful transactions under her belt, Partner, Jennifer Chasson, brings invaluable expertise to the table. Whether it’s guiding as an advisor, mentor underwriter, ...